The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.

The drugmaker met increased demand following approval of Carvykti in earlier lines of therapy with expanded production at US and European facilities.

The partners will incorporate BostonGene's Tumor Portrait tests into SCRI's Phase I clinical trials to explore the use of HLA typing for pre-screening patients.

The expert recommendations addressed clinical workflow, guideline creation, and reimbursement barriers to precision oncology.

The researchers previously received a single-patient approval to administer a second dose of the treatment in the study.